Nov 12 (Reuters) – Bristol Myers Squibb said on Thursday it will combine its scientific and clinical expertise teams into an end-to-end research and development department under current Chief Medical Officer Cristian Massacesi, effective January 1, 2027.
Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.
• “Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth,” said CEO Christopher Boerner
• Analysts are closely watching Bristol’s drug development pipeline for clues on growth
• “Under Cristian’s leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution,” Boerner said
(Reporting by Sneha S K in Bengaluru)
